drugset / Trial / NCT04762745
The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To explore the efficacy and safety of pomalidomide and bendamustine with dexamethasone in relapsed or refractory multiple myeloma
Timeline
- Start
- 2021-02
- Primary completion
- 2022-02
- Completion
- 2023-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Bendamustine | Small molecule | 70 mg/m2 | Intravenous |
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Pomalidomide | Other / unclassified | 4 mg | Oral |